{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-018482","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.715343+00:00","generated_at":"2026-06-02T06:30:10.152520+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ensysce Biosciences believes it regains Nasdaq stockholders' equity compliance after warrant exercise","bullets":["Company believes it now has at least $2.5M stockholders' equity, satisfying Nasdaq listing rule.","February 2024 warrant exercise generated gross proceeds of ~$4.7M.","Previously received Nasdaq extension to May 13, 2024 to evidence compliance.","Awaiting Nasdaq formal confirmation of compliance status."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-018482","json":"https://secwatch.observer/filing/0001493152-24-018482.json","markdown":"https://secwatch.observer/filing/0001493152-24-018482.md","text":"https://secwatch.observer/filing/0001493152-24-018482.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000149315224018482/0001493152-24-018482-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000149315224018482/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:30:10.152520+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}